This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase (NA) alongside haemagglutinin (HA) and leveraging DNA targeting sequences (DTS), the study demonstrates that dbDNA vaccines can elicit strong immune responses and broaden protection, particularly in cases where HA mutates but NA remains conserved.

Download the full article to learn:

• Insights into how combining HA and NA antigens can enhance the breadth and durability of influenza vaccine protection.
• The role of DNA targeting sequences in boosting immune responses within linear DNA vaccine platforms.
• The advantages of dbDNA technology for rapid, scalable, and cell-free vaccine production.